Kidney function may change how this drug works

NCT ID NCT07137689

Completed Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the drug LY3537982 is processed in people with different levels of kidney function. Researchers compared 32 participants with normal kidneys, moderate kidney problems, and severe kidney problems. The goal was to see how kidney impairment affects drug levels in the blood, which helps determine the right dose for people with kidney issues.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3537982 (oral drug)
What this could lead to: If successful, this study could help doctors determine the right dose of LY3537982 for people with kidney problems, making the drug safer and more effective for them.
What could go wrong: This is a small, early-stage study focused on drug levels, not on treating a disease. It does not test whether LY3537982 works for any condition, so results may not lead to a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL INSUFFICIENCY

Contacts and locations

Locations

Genesis Clinical Research

Tampa, Florida, 33603, United States
Jacksonville Center for Clinical Research

Jacksonville, Florida, 32216, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Panax Clinical Research

Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.